Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinuccia Valagussa

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Breast Cancer Research and Treatment|July 14, 2011
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Milvia Zambetti, Mauro Mansutti, Patricia Gomez, et al.
Cancer|July 9, 2004
Adult Wilms' tumor: A monoinstitutional experience and a review of the literatureMonica Terenziani, Filippo Spreafico, Paola Collini, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast Cancer Research : BCR|February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerLuca Gianni, Milvia Zambetti, Kim Clark, et al.
Lancet (London, England)|February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Clinical Genitourinary Cancer|April 24, 2016
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy FailureAndrea Necchi, Andrea Anichini, Daniele Raggi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma GroupAlessandro Gronchi, Sergio Frustaci, Mario Mercuri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni, José Baselga, Wolfgang Eiermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapyLuca Gianni, José Baselga, Wolfgang Eiermann, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|July 14, 2011
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Milvia Zambetti, Mauro Mansutti, Patricia Gomez, et al.
Cancer|July 9, 2004
Adult Wilms' tumor: A monoinstitutional experience and a review of the literatureMonica Terenziani, Filippo Spreafico, Paola Collini, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast Cancer Research : BCR|February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerLuca Gianni, Milvia Zambetti, Kim Clark, et al.
Lancet (London, England)|February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Clinical Genitourinary Cancer|April 24, 2016
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy FailureAndrea Necchi, Andrea Anichini, Daniele Raggi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma GroupAlessandro Gronchi, Sergio Frustaci, Mario Mercuri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni, José Baselga, Wolfgang Eiermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapyLuca Gianni, José Baselga, Wolfgang Eiermann, et al.
Pageof 6